Search
SOLACI Congress
HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

Anticoagulation and PCI: How Long Should Triple Therapy Last?

The aim of this study was to compare clinical outcomes in relation to the duration of triple...
solaci -
Learn More
Acute coronary syndromes

Intracoronary Abciximab reduces events in diabetics during PPCI

Diabetic patients have an increased risk of future cardiovascular events after an ST elevation MI. Administration of...
solaci -
Learn More
Antiplatelet

Ticagrelor: Similar to Aspirin in Patients with Stroke or TIA

Ticagrelor might be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and...
solaci -
Learn More
Antiplatelet

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that...
solaci -
Learn More
Antiplatelet

Optimal Duration of DAPT: How to Predict Long-Term Events

Courtesy of Dr. Santiago F. Coroleu.   Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention...
solaci -
Learn More
Antiplatelet

Ticagrelor Reduces Events in Diabetics with Prior MI

    All studies on diabetics have shown these patients have higher risk rates of thrombotic events. This study...
solaci -
Learn More
Antiplatelet

DAPT after PCI with EES: 6 or 12 Months?

Original Title: 6-Month versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial. Reference:...
solaci -
Learn More
Antiplatelet

Does Ticagrelor Reduce Events in Peripheral Artery Disease?

Original Title: Ticagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease. Reference:...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy